The role of C1 inhibitor and complement as acute phase reactants: are we missing the diagnosis of hereditary angioedema?
Related Experiment Video
Updated: Oct 17, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Peter Stepaniuk1, Ana-Maria Bosonea2, Persia Pourshahnazari3
1Division of Allergy and Immunology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. peter.stepaniuk@alumni.ubc.ca.
Background:
C1 inhibitor (C1-INH) and complement 4 (C4) have historically been referred to as positive acute phase reactants, however this has never been evaluated in hereditary angioedema (HAE) patients. Low function of C1-INH and low levels of C4 are important in the diagnosis of HAE type 1 and 2. If C1-INH and/or C4 are significant acute phase reactants, their levels may be falsely "normal" in patients with HAE when measured during times of infection or inflammation resulting in missed or delayed diagnosis.
Case Presentation:
We present a case series of four HAE patients who had C4, C1-INH, c-reactive protein (CRP) and ferritin measured at baseline and again during a self-reported upper respiratory tract infection (URTI) or flu-like illness. We did not identify any HAE patients who had a significant change in their C1-INH functional level in the context of a mild infection. However, the C4 level did increase into the normal range on three occasions (2 patients, with 1 patient having elevation during two separate illnesses).
Conclusions:
C1 inhibitor may not be a clinically significant acute phase protein and appears to still be a reliable diagnostic marker of hereditary angioedema, even in times of modest acute inflammation, unlike complement C4 which can be elevated in this setting.
More Related Videos
06:54Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
Published on: June 15, 2019
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
Related Concept Videos
Complement System
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Allergic Reactions
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
GPCRs Regulate Adenylyl Cylase Activity